Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004 Aug 24;101(34):12604-9.
doi: 10.1073/pnas.0405077101. Epub 2004 Aug 13.

Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia

Affiliations

Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia

Michael F Egan et al. Proc Natl Acad Sci U S A. .

Abstract

GRM3, a metabotropic glutamate receptor-modulating synaptic glutamate, is a promising schizophrenia candidate gene. In a family-based association study, a common GRM3 haplotype was strongly associated with schizophrenia (P = 0.0001). Within this haplotype, the A allele of single-nucleotide polymorphism (SNP) 4 (hCV11245618) in intron 2 was slightly overtransmitted to probands (P = 0.02). We studied the effects of this SNP on neurobiological traits related to risk for schizophrenia and glutamate neurotransmission. The SNP4 A allele was associated with poorer performance on several cognitive tests of prefrontal and hippocampal function. The physiological basis of this effect was assessed with functional MRI, which showed relatively deleterious activation patterns in both cortical regions in control subjects homozygous for the SNP4 A allele. We next looked at SNP4's effects on two indirect measures of prefrontal glutamate neurotransmission. Prefrontal N-acetylaspartate, an in vivo MRI measure related to synaptic activity and closely correlated with tissue glutamate, was lower in SNP4 AA homozygotes. In postmortem human prefrontal cortex, AA homozygotes had lower mRNA levels of the glial glutamate transporter EAAT2, a protein regulated by GRM3 that critically modulates synaptic glutamate. Effects of SNP4 on prefrontal GRM3 mRNA and protein levels were marginal. Resequencing revealed no missense or splice-site SNPs, suggesting that the intronic SNP4 or related haplotypes may exert subtle regulatory effects on GRM3 transcription. These convergent data point to a specific molecular pathway by which GRM3 genotype alters glutamate neurotransmission, prefrontal and hippocampal physiology and cognition, and thereby increased risk for schizophrenia.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Effects of GRM3 genotype on prefrontal and hippocampal physiological responses. (A) Brain map showing locales where SNP4 genotype groups differed in blood oxygenation measured with fMRI during a working memory task (the N back). Locales marked in red are groups of voxels where subjects with the A/A genotype showed higher activation and were significantly different when compared with a combined group of A/G and G/G subjects. One large cluster (k = 10) is in the dorsolateral prefrontal cortex (Brodmann Area 46) for A/A>A/G and G/G. (B) Brain map showing locales in hippocampus where SNP4 genotype differed in blood oxygenation during an episodic memory task. The region marked in red is an activation cluster (k = 9) where healthy subjects with the A/A genotype showed reduced activation relative to A/G and G/G subjects.
Fig. 2.
Fig. 2.
Distribution of EAAT2 mRNA levels (μCi/g) from the dorsolateral prefrontal cortex (superficial layers) by GRM3 SNP4 genotype (see text for statistics). •, controls; ○, probands.

Similar articles

Cited by

References

    1. Weinberger, D. R., Egan, M. F., Bertolino, A., Callicott, J. H., Mattay, V. S., Lipska, B. K., Berman, K. F. & Goldberg, T. E. (2001) Biol. Psychiatry 50, 825–844. - PubMed
    1. Goldberg, T. E. & Weinberger, D. R. (1988) Schizophr. Bull. 14, 179–183. - PubMed
    1. Callicott, J. H., Bertolino, A., Mattay, V. S., Langheim, F. J. P., Duyn, J., Coppola, R., Goldberg, T. E. & Weinberger, D. R. (2000) Cereb. Cortex 10, 1078–1092. - PubMed
    1. Selemon, L. D. & Goldman-Rakic, P. S. (1999) Biol. Psychiatry 45, 17–25. - PubMed
    1. Deakin, J. F., Slater, P., Simpson, M. D., Gilchrist, A. C., Skan, W. J., Royston, M. C., Reynolds, G. P. & Cross, A. J. (1989) J. Neurochem. 52, 1781–1786. - PubMed

Substances